← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Dare Bioscience, Inc.
San Diego, CA
$6,189,677
Total funding
6
Grants
Funding over time
peak $2M · FY2018–25$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,189,677 · 6
By mechanism
R44$5,245,755 · 3
R43$558,950 · 2
R41$384,972 · 1
Investigators at Dare Bioscience, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A novel intravaginal ring technology featuring the sustained release of natural progesterone for the prevention of preterm birth in at-risk women$1,016,258
R44 · FY2025 · HD
A first-in-class product for the clearance of high-risk human papillomaviruses$1,000,000
R44 · FY2025 · AI
A novel intravaginal ring technology featuring the sustained release of natural progesterone for the prevention of preterm birth in at-risk women$991,573
R44 · FY2024 · HD
Safety, and acceptability of a non-hormonal vaginal ring$982,851
R44 · FY2019 · HD
Safety, and acceptability of a non-hormonal vaginal ring$730,722
R44 · FY2020 · HD
Therapeutic targeting of FKBP51 for the prevention of stress-induced preterm birth$384,972
R41 · FY2023 · HD
Subcutaneous insertion and removal of a user-controlled, long-acting, and reversible contraceptive device$309,614
R43 · FY2021 · HD
A novel intravaginal ring technology featuring the sustained release of natural progesterone for the prevention of preterm birth in at-risk women$299,696
R44 · FY2020 · HD
Defining end-user preferences among US women to optimize the design of a long-acting injectable hormonal contraceptive$249,336
R43 · FY2022 · HD
Safety, and acceptability of a non-hormonal vaginal ring$224,655
R44 · FY2018 · HD